Company Biohaven Ltd.

Equities

BHVN

VGG1110E1079

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

End-of-day quote Nyse Other stock markets 18:00:00 2024-05-09 EDT			5-day change	1st Jan Change
35.69 ^USD	-13.71%		-12.29%	-16.61%

05-10	Biohaven Shares Fall as Q1 Loss Widens, Misses Estimates	MT
04-25	Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing	MT

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.

Number of employees: 239

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	88,258,441	72,267,468 ( 81.88 %)	0	81.88 %

Name	Equities	%	Valuation
John Childs 7.808 %	6,375,744	7.808 %	349 M $
Vanguard Fiduciary Trust Co. 7.726 %	6,308,853	7.726 %	345 M $
Stifel Independent Advisors LLC 7.624 %	6,225,811	7.624 %	340 M $
Janus Henderson Investors US LLC 7.227 %	5,901,343	7.227 %	323 M $
Janus Henderson Investors US LLC 7.227 %	5,901,343	7.227 %	323 M $
BlackRock Advisors LLC 6.603 %	5,392,499	6.603 %	295 M $
Suvretta Capital Management LLC 5.600 %	4,572,836	5.600 %	250 M $
STATE STREET CORPORATION 4.740 %	3,870,839	4.740 %	212 M $
Vladimir Coric 3.853 %	3,146,085	3.853 %	172 M $
T. Rowe Price International Ltd. 3.838 %	3,134,323	3.838 %	171 M $

Biohaven Ltd.

215 Church Street

06510, New Haven

http://www.biohaven.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

35.69 USD

Average target price

57.67 USD

Spread / Average Target

+61.58%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOHAVEN LTD.	-16.61%	3.15B
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research